早期乳腺癌的基因表达特征：与临床病理特征相结合更好。

Gene expression signatures in early breast cancer: Better together with clinicopathological features.

机构信息

Grupo Oncoclínicas (GOC), Centro Paulista de Oncologia (CPO) - Unidade Faria Lima, Av. Brigadeiro Faria Lima, 4300, São Paulo, SP 04538-132, Brazil.

出版信息

Crit Rev Oncol Hematol. 2022 Jul;175:103708. doi: 10.1016/j.critrevonc.2022.103708. Epub 2022 May 14.

DOI:10.1016/j.critrevonc.2022.103708

PMID:35580764

Abstract

Breast cancer (BC) is a highly heterogeneous disease, characterized by a variety of subtypes with distinct biological, molecular, and clinical behavior. Standard clinicopathological and tumor biology information (as assessed by gene expression signatures-GES), have provided enhanced prognostic and predictive information in both node-negative(N0) and positive(N +), hormonal receptor positive/human epidermal growth factor 2 negative (HR+/HER2-) early breast cancer (EBC). Herein, we comprehensively review the clinical data of 5 commonly used GES, namely, Oncotype DX(ODX)®; MammaPrint (MP)®; Prosigna®; Breast Cancer Index (BCI)® and Endopredict® - with sections specifically addressing the role of GES in special histologic subtypes, premenopausal women, late recurrence and adjuvant treatment de-escalation.

摘要

乳腺癌（BC）是一种高度异质性的疾病，其特点是存在多种具有不同生物学、分子和临床行为的亚型。标准的临床病理和肿瘤生物学信息（通过基因表达谱评估-GES），为淋巴结阴性（N0）和阳性（N+）、激素受体阳性/人表皮生长因子 2 阴性（HR+/HER2-）早期乳腺癌（EBC）患者提供了增强的预后和预测信息。在此，我们全面回顾了 5 种常用 GES 的临床数据，即 Oncotype DX（ODX）®；MammaPrint（MP）®；Prosigna®；Breast Cancer Index（BCI）®和 Endopredict® - 特别针对 GES 在特殊组织学亚型、绝经前妇女、晚期复发和辅助治疗降级中的作用进行了介绍。